News Brief
AstraZeneca Admits Its Covishield Vaccine Can Cause Rare Side Effects: Here's What They Are
Kuldeep Negi
Apr 30, 2024, 08:51 AM | Updated 08:50 AM IST
Save & read from anywhere!
Bookmark stories for easy access on any device or the Swarajya app.
British pharmaceutical giant AstraZeneca has acknowledged that its Covid vaccine, Covishield, can lead to a rare side effect.
According to court documents, the vaccine can cause a condition resulting in blood clots and a low platelet count, although this occurrence is rare.
Covishield, a vaccine developed by AstraZeneca and Oxford University during the Covid-19 pandemic, was manufactured by the Serum Institute of India and extensively distributed in the country.
AstraZeneca is currently embroiled in a class-action lawsuit in the UK, with claimants asserting that the vaccine led to deaths and severe injuries in multiple instances.
In the UK High Court, 51 cases are seeking damages of up to £100 million.
The first complainant in the case, Jamie Scott, alleged that after receiving the vaccine in April 2021, he suffered a permanent brain injury due to a blood clot, rendering him unable to work and the hospital even told his wife thrice that he's going to die.
AstraZeneca has refuted these claims but did concede in a court document from February that Covishield can, in extremely rare circumstances, induce Thrombosis with Thrombocytopenia Syndrome (TTS), which manifests as blood clots and low platelet count.
"It is admitted that the AZ vaccine can, in very rare cases, cause TTS. The causal mechanism is not known...Further, TTS can also occur in the absence of the AZ vaccine (or any vaccine). Causation in any individual case will be a matter for expert evidence," AstraZeneca said, NDTV reported.
The admission made by AstraZeneca forms part of its legal defence in Scott's case, potentially leading to compensation for victims and their families.
Notably, this admission contrasts with the company's previous stance in 2023 when it denied that TTS was linked to the vaccine on a generic level.
However, AstraZeneca has denied the lawyers' claims that the vaccine is "defective" and its efficacy "vastly overstated".
Save & read from anywhere!
Bookmark stories for easy access on any device or the Swarajya app.
Kuldeep is Senior Editor (Newsroom) at Swarajya. He tweets at @kaydnegi.
Support Swarajya's 50 Ground Reports Project & Sponsor A Story
Every general election Swarajya does a 50 ground reports project.
Aimed only at serious readers and those who appreciate the nuances of political undercurrents, the project provides a sense of India's electoral landscape. As you know, these reports are produced after considerable investment of travel, time and effort on the ground.
This time too we've kicked off the project in style and have covered over 30 constituencies already. If you're someone who appreciates such work and have enjoyed our coverage please consider sponsoring a ground report for just Rs 2999 to Rs 19,999 - it goes a long way in helping us produce more quality reportage.
You can also back this project by becoming a subscriber for as little as Rs 999 - so do click on this links and choose a plan that suits you and back us.
Click below to contribute.